Hemab
Camilla Petrycer Hansen, PhD, Cand. Pharm, is a Principal at Novo Holdings and a Hemab Board Observer. Previously, she served as Senior Manager, Business Development at Novozymes and Business Development Manager at Statens Serum Institut. She earned a PhD in Medicinal Chemistry and a Cand. Pharm. in Pharmaceutical Sciences from the University of Copenhagen, Denmark.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.